<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059796</url>
  </required_header>
  <id_info>
    <org_study_id>Gemini III Rev 2</org_study_id>
    <nct_id>NCT04059796</nct_id>
  </id_info>
  <brief_title>Comparison of Gemini III Rev 2 Implanted in Conjunction With an Approved IOL vs Eyes Implanted With an Approved IOL</brief_title>
  <official_title>Clinical Investigation of OMEGA Gemini Capsule, Model Gemini Capsule 3 Rev 2 in Combination With a Commercially Available, FDA Approved Monofocal or Toric Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omega Ophthalmics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omega Ophthalmics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, observational, randomized, controlled, paired eye,&#xD;
      subject-masked design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomly assigned to which eye will receive the Omega capsule Gemini 3 with&#xD;
      an approved monofocal or Toric intraocular lens. Fellow eyes will receive an approved&#xD;
      monofocal or Toric IOL (no Omega capsule).&#xD;
&#xD;
      Eyes randomized to receive one of the Gemini capsules (both models) will be eligible to have&#xD;
      a secondary procedure (post 1-month postoperative visit) to correct refractive error.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Actual">August 28, 2020</completion_date>
  <primary_completion_date type="Actual">August 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subjects will be masked to which eye receives the study device</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of fusion of peripheral anterior and posterior capsule to the intraocular lens</measure>
    <time_frame>6 month Postop Visit</time_frame>
    <description>Via dilated slit lamp examination subjects will be assessed for anterior and posterior Via dilated slit lamp examination subjects will be assessed for anterior and posterior fusion of the IOL to the capsular bag with a dichotomous &quot;Yes/No&quot; response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Study Eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study device in conjunction with an approved monofocal or toric IOL after cataract extraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Eye</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>approved monofocal or toric IOL after cataract extraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Omega Gemini III Rev 2 Device</intervention_name>
    <description>Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction</description>
    <arm_group_label>Study Eye</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Eye</intervention_name>
    <description>Control eyes will receive an approved monofocal or toric IOL post cataract extraction</description>
    <arm_group_label>Control Eye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 years of age or older at the time of surgery diagnosed with bilateral cataracts&#xD;
&#xD;
          -  Able to understand and sign an informed consent&#xD;
&#xD;
          -  Willing and able to complete all study visits and assessments required for the study&#xD;
&#xD;
          -  Calculated lens power within the available range&#xD;
&#xD;
          -  Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or&#xD;
             without a glare source present&#xD;
&#xD;
          -  Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag&#xD;
             fixated IOL implantation&#xD;
&#xD;
          -  Potential postop visual acuity of 20/25 or better in the judgment of the surgeon&#xD;
&#xD;
          -  Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography&#xD;
&#xD;
          -  Clear intraocular media other than cataract&#xD;
&#xD;
          -  Preop endothelial cell density of 2000 cells/mm2 or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject's best corrected vision is light perception or no light perception in either&#xD;
             eye&#xD;
&#xD;
          -  Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal&#xD;
             and macular examination.&#xD;
&#xD;
          -  Orbital abnormalities, such as thyroid related orbitopathy, causing significant&#xD;
             exophthalmos.&#xD;
&#xD;
          -  Eyelid abnormalities causing lagophthalmos.&#xD;
&#xD;
          -  Significant anterior blepharitis or meibomian gland dysfunction&#xD;
&#xD;
          -  Corneal abnormalities or conditions, other than regular topographic corneal&#xD;
             astigmatism&#xD;
&#xD;
          -  Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)&#xD;
&#xD;
          -  Abnormalities of the iris including trans-illumination defects&#xD;
&#xD;
          -  Pupil abnormalities (abnormally shaped, fixed or non-reactive)&#xD;
&#xD;
          -  Pharmacologic dilation less than 7 mm&#xD;
&#xD;
          -  Axial length &lt;22.5mm&#xD;
&#xD;
          -  Lens thickness &lt;4.1 mm&#xD;
&#xD;
          -  Anterior chamber depth &gt;2.8mm&#xD;
&#xD;
          -  Extremely shallow anterior chamber &lt;2.0mm&#xD;
&#xD;
          -  Prior ocular surgery&#xD;
&#xD;
          -  Epiretinal membrane&#xD;
&#xD;
          -  Macular edema&#xD;
&#xD;
          -  Retinal tears including operculated holes&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Glaucoma of any kind&#xD;
&#xD;
          -  Pseudoexfoliation syndrome&#xD;
&#xD;
          -  History of uveitis/iritis&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Acute, chronic or uncontrolled systemic or ocular disease that may confound the&#xD;
             results of the study (including rheumatologic conditions such as Rheumatoid arthritis,&#xD;
             ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic&#xD;
             neuritis or multiple sclerosis).&#xD;
&#xD;
          -  Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo)&#xD;
             or similar medications&#xD;
&#xD;
          -  Average Keratometry &lt;38D or &gt; 48D by topography&#xD;
&#xD;
          -  Any pathology of the zonules including evidence of zonular weakness, zonular&#xD;
             instability, zonular damage, or coloboma effecting zonules.&#xD;
&#xD;
          -  History of ocular trauma&#xD;
&#xD;
          -  Pregnant, lactating, or has another condition with associated fluctuation of hormones&#xD;
             that could lead to refractive changes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Orlich, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Clinica 20/20</name>
      <address>
        <city>San José</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

